Targeted anticytokine therapy and the failing heart

被引:72
作者
Mann, DL
机构
[1] Winters Ctr Heart Failure Res, Cardiol Sect, Dept Med, Michael E DeBakey Vet Adm Med Ctr, Houston, TX 77030 USA
[2] Baylor Coll Med, Houston, TX 77030 USA
[3] Methodist DeBakey Heart Ctr, Houston, TX USA
关键词
D O I
10.1016/j.amjcard.2005.03.007
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Recent studies have identified the importance of proinflammatory mediators in the development and progression of chronic heart failure (CHF). The growing appreciation of the pathophysiologic consequences of sustained expression of proinflammatory mediators in preclinical and clinical CHF models culminated in a series of multicenter clinical trials that used targeted approaches to neutralize tumor necrosis factor in patients with moderate-to-advanced CHF. However, these targeted approaches have resulted in worsening CHF, thereby raising a number of important questions about what role, if any, proinflammatory cytokines play in the pathogenesis of CHF. This review summarizes what has been learned from the negative clinical trials, as well as the potential direction of future research in this area. (c) 2005 by Excerpta Medica Inc.
引用
收藏
页码:9C / 16C
页数:8
相关论文
共 47 条
[1]   Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy [J].
Aukrust, P ;
Ueland, T ;
Lien, E ;
Bendtzen, K ;
Müller, F ;
Andreassen, AK ;
Nordoy, I ;
Aass, H ;
Espevik, T ;
Simonsen, S ;
Froland, SS ;
Gullestad, L .
AMERICAN JOURNAL OF CARDIOLOGY, 1999, 83 (03) :376-382
[2]   Cytokines as emerging targets in the treatment of heart failure [J].
Baumgarten, G ;
Knuefermann, P ;
Mann, DL .
TRENDS IN CARDIOVASCULAR MEDICINE, 2000, 10 (05) :216-223
[3]   COMPARATIVE NEUROHORMONAL RESPONSES IN PATIENTS WITH PRESERVED AND IMPAIRED LEFT-VENTRICULAR EJECTION FRACTION - RESULTS OF THE STUDIES OF LEFT-VENTRICULAR DYSFUNCTION (SOLVD) REGISTRY [J].
BENEDICT, CR ;
WEINER, DH ;
JOHNSTONE, DE ;
BOURASSA, MG ;
GHALI, JK ;
NICKLAS, J ;
KIRLIN, P ;
GREENBERG, B ;
QUINONES, MA ;
YUSUF, S .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1993, 22 (04) :A146-A153
[4]   Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure [J].
Bozkurt, B ;
Torre-Amione, G ;
Warren, MS ;
Whitmore, J ;
Soran, OZ ;
Feldman, AM ;
Mann, DL .
CIRCULATION, 2001, 103 (08) :1044-1047
[5]   Pathophysiologically relevant concentrations of tumor necrosis factor-α promote progressive left ventricular dysfunction and remodeling in rats [J].
Bozkurt, B ;
Kribbs, SB ;
Clubb, FJ ;
Michael, LH ;
Didenko, VV ;
Hornsby, PJ ;
Seta, Y ;
Oral, H ;
Spinale, FG ;
Mann, DL .
CIRCULATION, 1998, 97 (14) :1382-1391
[6]   Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-α, in patients with moderate-to-severe heart failure -: Results of the Anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial [J].
Chung, ES ;
Packer, M ;
Lo, KH ;
Fasanmade, AA ;
Willerson, JT .
CIRCULATION, 2003, 107 (25) :3133-3140
[7]   PLASMA NOREPINEPHRINE AS A GUIDE TO PROGNOSIS IN PATIENTS WITH CHRONIC CONGESTIVE HEART-FAILURE [J].
COHN, JN ;
LEVINE, TB ;
OLIVARI, MT ;
GARBERG, V ;
LURA, D ;
FRANCIS, GS ;
SIMON, AB ;
RECTOR, T .
NEW ENGLAND JOURNAL OF MEDICINE, 1984, 311 (13) :819-823
[8]  
Deswal A, 2001, CIRCULATION, V103, P2055
[9]   Safety and efficacy of a soluble P75 tumor necrosis factor receptor (enbrel, etanercept) in patients with advanced heart failure [J].
Deswal, A ;
Bozkurt, B ;
Seta, Y ;
Parilti-Eiswirth, S ;
Hayes, FA ;
Blosch, C ;
Mann, DL .
CIRCULATION, 1999, 99 (25) :3224-3226
[10]  
Deswal A, 2001, Heart Fail Rev, V6, P143